Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare ...

Dr. Reddy's, Sun Pharma, Zydus & others launch branded generics after patent expiry, targeting a ₹12,000-crore market ...

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

GLP-1 therapies have expanded beyond diabetes and obesity treatment, displaying vascular and potential mental health benefits ...

A 40–50% price drop in GLP-1 weight-loss drugs like Ozempic could boost access in India. Experts weigh in on benefits, risks, ...

At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

The Hoffman Process, popular with a growing number of CEOs and celebrities, is often described as ‘10 years of therapy in a ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an ...

Detailed price information for Southern Silver Exploration Corp. (SSV-X) from The Globe and Mail including charting and ...